Jain Global’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jain Global’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-43,027	Closed	-$2.07M	–	1909
2026 Q1	$2.07M	Buy	43,027 +11,221	+35%	+$497K	0.01%	678
2025 Q4	$1.31M	Buy	31,806 +10,879	+52%	+$436K	0.01%	667
2025 Q3	$813K	Sell	20,927 -34,627	-62%	-$1.13M	﹤0.01%	673
2025 Q2	$1.54M	Buy	+55,554	New	+$1.41M	0.01%	556

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Jain Global's KNSA Position: Q2 2026 in Review

Jain Global sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 43,027 shares — an estimated $2.07M sold.

Jain Global first reported a position in KNSA in Q2 2025 and held it in 4 quarters. The position peaked at $2.07M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Jain Global reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jain Global sold 43,027 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.07M.
Jain Global first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Jain Global's Kiniksa Pharmaceuticals position peaked at $2.07M in Q1 2026.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.